I n the last decade, the incidence of cutaneous melanoma has been steadily increasing in North America. 1 Early detection and removal of melanoma primary lesions of Ͻ1.5 mm Breslow thickness at early stages of progression is often associated with favorable prognosis. 2 However, greater depths of a primary lesion or presence of metastatic disease is often associated with a poor prognosis. There are a variety of treatments available for patients with poor prognosis such as chemotherapy, active-specific immunotherapy (vaccine), cytokine therapy, and biochemotherapy that have shown some promising clinical responses. [3] [4] [5] [6] In addition, many new treatments are being developed that need to be validated in randomized clinical trials. To date, although these therapeutic interventions may prolong survival, there is basically no cure rate for advanced disease. Recently, gene therapies involving direct or indirect gene transfer have been proposed as treatment for cancer including malignant melanoma. These modalities include delivery to tumor cells, vaccination with tumorassociated antigen(s) (Ags), and delivery of specific cytokine(s) for immunomodulation or modulation of tumor cell growth and properties. [7] [8] [9] [10] [11] The delivery of cytostatic cytokines such as interferon-␥ (IFN-␥) has shown promising results in animal and human studies. IFN-␥ is a type II IFN, whereas IFN-␣ and IFN-␤ are type I. 12 Type II IFN is predominantly produced from effector T cells and has been shown to have a role in regulating tumor cell growth and properties as well as activation of Ag presentation. [13] [14] [15] IFN-␥ has been shown to modulate cell surface Ag expression of melanoma cells, thereby enhancing their antigenicity and susceptibility to attack by effector cells. 13, 14 Local expression of IFN-␥-producing cells in the vicinity of the tumor is believed to be active in promoting regional tumor immunity. IFN-␥ has been shown to have strong growth inhibitory and modulatory effects on melanoma cells in culture. 13 Clinical protocols involving infusion of IFN-␥ into patients to induce systemic immunity have not been that promising to date due to high toxicity. treatment with IFN-␥ are its half-life and the sensitivity of the tumor to the IFN-␥ treatment dose.
The direct i.t. or peritumoral injection of vectors expressing murine IFN-␥ has been shown to be effective in inducing systemic antitumoral immune responses and significant regional and systemic antitumoral effects. 8, 9 In a phase I clinical trial involving a single injection of IFN-␥ retroviral vector every day for 5 days, no significant toxicity occurred and no replication-competent retrovirus was detected by polymerase chain reaction (PCR). 17, 18 This initial study showed transgene expression, clinical safety, and suggestive clinical activity. The main purpose of the current study was to determine tolerability and evidence of antitumoral activity after multiple i.t. injections of IFN-␥ retroviral vector. In this report, we assessed the anti-melanoma-associated Ag (MAA) specific antibody (Ab) response to four MAA known to be immunogenic and to induce Ab responses in humans. 19 -21 The MAA assessed are known to be expressed in melanomas with fairly high frequency. [22] [23] [24] [25] Previously, we have demonstrated that elevated immunoglobulin G (IgG) to specific MAA correlated with a better prognosis in clinically disease-free American Joint Committee on Cancer (AJCC) stage III melanoma patients who received melanoma cell vaccine. 19, 20 The objective of the present study was to determine whether there was a significant enhancement and correlation in anti-MAA Ab responses after treatment with single or multiple courses of IFN-␥ retroviral vector. To perform this study, recombinant MAA were synthesized and anti-MAA specific enzyme-linked immunosorbent assays (ELISAs) were developed to assess the IgG Ab responses of patients.
MATERIALS AND METHODS

Patients
Patients accrued in the study had metastatic melanoma for which standard treatment measures do not exist and showed evidence of a new disease site or a 25% increase in disease level after the last treatment. Patients accrued in the study were Ն18 years of age with an expected survival of a least 9 months. Entry into the study required patients to have at least one tumor nodule between 1 and 5 cm 2 peripherally located and accessible by injection and one distal nodule for assessment of systemic immune response to therapy. Stable performance status (ECOG 0 -1), a hematocrit of Ն30%, a white blood cell count of Ն3000/mm 3 , a platelet count of Ն90,000/ mm 3 , a SGOT and SGPT of Ͻ3 ϫ the upper limit of normal, a bilirubin level of Ͻ2.0 mg/dL, and prothrombin time/partial thromboplastin time in normal limits were required. Patients were required to have negative serology for HIV and hepatitis B and C. All patients signed an informed consent required by institutional policy. Pregnant or lactating women and patients who received prior cancer vaccines were excluded. Patients entering into the study had no surgery, chemotherapy, radiotherapy, or investigational reagents within 4 weeks before treatment. No prior radiotherapy to the treatment lesions was allowed for entry into the study.
Retroviral vector
The retroviral vector containing the human IFN-␥ used in the study has been described previously. 18 Briefly, human IFN-␥ cDNA was subcloned into an N2-based vector backbone derived from the Moloney murine leukemia virus to generate the proviral vector plasmid. The Moloney murine leukemia long terminal repeat controls the expression of the IFN-␥ gene, and an internal simian virus 40 promoter drives the expression of the neomycin-resistant selectable markers. The construct was cotransfected with a vesicular stomatitis virus-g protein expression vector into an amphotropic canine packaging cell line (DA) and the supernatant collected was used to generate vector-producing cell lines from the DA packaging cell line. Individual clones were isolated and characterized for various characteristics as described previously. 18 Retroviral vector production was as described previously. 18, 26 Briefly, a vial of IFN-␥ vector-producing cell line was thawed from a working cell bank and expanded in a culture flask. After several days in culture, the supernatant (total amount 200 L) was harvested daily for ϳ5 days. The supernatant was clarified, concentrated, and diafiltered with an isotonic equilibration buffer. The vector was then purified over a Sephacryl S-500 size exclusion column (Pharmacia, Piscataway, NJ), further concentrated using tangential flow ultrafiltration, and formulated in a solution containing lactose, human serum albumin, and buffer. The final product was then tested for contaminating replication-competent retrovirus and sterility and then titrated. 7 plaque-forming units/mL/day) for 5 consecutive days (0.3 mL for the first cohort, 0.5 mL for the second cohort, and 1.0 mL for the third cohort per injection). Patients in the second three cohorts were treated with the same dose levels (0.3, 0.5, and 1.0 mL/injection for 5 consecutive days) and treated for six cycles. A cycle was defined as five daily injections every 2 weeks. Continuation of treatment was allowed based on the following criteria: (a) the patient did not experience grade III/IV drug-related toxicity; (b) the patient did not require other therapy for optimal management of his/her disease; and (c) the injected site of disease remained stable or decreased in size.
Study design
Patient evaluation
Clinical, immunological, and laboratory testing were completed within 30 days before treatment: complete history and physical examination; tumor assessment by radiological technique (noting in detail the exact size and location of any lesions that existed); computed tomography (CT)/magnetic resonance imaging of the head, chest, and abdomen; electrocardiogram; complete blood count; differential platelet count; replicationcompetent retrovirus sampling; Ab testing; and various other laboratory tests. History, physical examination, and blood specimens for laboratory tests as well as for Ab analysis were done just before each injection. On weeks 3, 5, 7, 9, and 11, history, physical examination, and blood were taken for laboratory tests. At the end of the study (week 16), history; physical examination; tumor assessment (including radiological technique for evaluation of all lesions); repeat CT of the head, chest, and abdomen; and collection of blood specimens for laboratory tests were performed.
Clinical responses were assessed as follows: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). A CR was considered to be a complete disappearance of all tumors with resolution of all symptoms and all laboratory abnormalities attributable to tumor, documented on two evaluations using identical methodology, and separated by at least 28 days. Pertinent organ systems were evaluated to rule out the presence of tumor lesions. The first day of CR is the first date on which all evaluable lesions disappeared. Tumors were measured bidimensionally. A PR was defined as a Ն50% reduction in the sum of the products of tumor dimensions for measurable lesions compared with baseline, without an increase in the size of any lesion of Ն25%. In addition, improvement or stabilization of evaluable lesions and improvement or stabilization of patient symptoms and laboratory abnormalities attributable to tumor was required. Documentation was obtained on evaluations using identical methodology separated by at least 28 days. Every site of known disease was evaluated to rule out progression of tumor lesions. SD was defined as no change in size or lesions or as an increase or decrease of Ͻ25% and no appearance of new lesions for at least 28 days. PD was defined as a Ն25% increase in the size of any single lesion or as the appearance of any new lesion.
Recombinant MAA proteins
Total RNA was prepared from human melanoma cell lines and reverse transcribed into cDNA as described previously. 20 The open-reading frame cDNA of MAGE-A1 (927 bp) tyrosinase (1356 bp), TRP-1 (1509 bp), TRP-2 (1356 bp), and gp100/ pmel17 (1932 bp) were amplified by PCR using primers designed based on GenBank sequences. The primers had appropriate restriction enzyme sites for cloning into the expression vector plasmids. The PCR products obtained were digested with respective restriction enzymes and cloned into an expression vector, pGEX/HIS, allowing the expression of glutathione S-transferase (GST) fusion protein with a Cterminal 6ϫ His affinity tag after induction. The pGEX/HIS vector was reengineered from the pGEX-2T vector (Pharmacia) by inserting a DNA fragment containing multiple cloning sites followed by a 6ϫ His tag into the SmaI site. The specificity of the MAA insert was verified as described previously. 20 
Expression and purification of recombinant MAA proteins
The MAA expression plasmids were transformed into Escherichia coli strain BL21 or DH5␣ cells. Recombinant fusion proteins were induced by isopropyl 223-D-thiogalactoside and purified from bacterial lysates by affinity chromatography using glutathione Sepharose 4B (Pharmacia). The GST fusion proteins of MAA were bound to the affinity column and then the recombinant proteins alone were cleaved from the GST carrier by thrombin and eluted from the column. The affinity-purified recombinant proteins were further purified by preparative sodium dodecyl sulfate gel electrophoresis using a Model 491 Prep Cell (Bio-Rad, Richmond, Calif) and/or through an anion exchange "Q" column using the Bio-Rad fast protein liquid chromatography system according to the manufacturer's instructions. The final purified recombinant proteins were analyzed by Western blotting using an Ni 2ϩ -nitrilotriacetic acid conjugate (Qiagen, Chatsworth, Calif) and the sera of respective positive melanoma patients.
Affinity anti-MAA ELISA
An affinity ELISA was performed with purified recombinant human MAA proteins (TRP-2, gp100, MAGE-A1, and tyrosinase) containing 6ϫ His tag, as described previously. 20 Briefly, recombinant protein (4 g/well) was incubated overnight at room temperature in ELISA 96-well microtiter plates coated with chelated nickel (Pierce, Rockford, Ill). After blocking by Sea blocking buffer (Pierce), sera were added in 2-fold dilutions from 1:25 to 1:3200 in phosphate-buffered saline (PBS) (pH 7.2) and incubated for 2 hours at room temperature in duplicate. After washing with PBS, goat anti-human IgG (␥-chain specific) horseradish peroxidase conjugate (Boehringer Mannheim, Indianapolis, Ind) was added and the plates were incubated for 1.5 hours at room temperature. After washing five times with PBS, plates were developed with ortho-phenylenediamine sodium citrate solution plus 6 N HCl and then read at 490 nm using an ELISA reader (Molecular Devices, Palo Alto, Calif). Sera from normal volunteer donors previously assessed to be negative for the individual MAA were used as negative controls in all assays. Positive controls were from melanoma patients previously assessed with high anti-MAA Ab titers. Patient Ab titers were defined as the highest serum dilution yielding an absorption rate greater than the normal donor volunteer serum absorption mean plus two SDs. All blood samples were titrated out for each MAA until a nonsignificant value above normal donor serum levels was reached as described above. Results are presented for individual anti-MAA responses as the maximum titer obtained for each blood sample.
Statistics
The following statistical analyses were performed: Wilcoxon rank-sum test, sign rank test, and 2 test.
RESULTS
Clinical findings
In the study, 17 patients with AJCC stage IV melanoma were entered into the trial. All patients were evaluable for tolerability and response to treatment. In Table 1 patients' treatment dose, disease injection site, tumor size, and site of metastatic disease are shown. Patients were divided into two groups: Group I (n ϭ 9 patients) received a single course (one cycle) of treatment; group II (n ϭ 8 patients) received multiple cycles (six cycles) of treatments (Tables 1 and 2 ). The first three cohorts of patients received a single course of treatment for 5 consecutive days (0.3 mL for the first cohort, 0.5 mL for the second cohort, and 1.0 mL for the third cohort per injection). The second three cohorts received the same dose levels (0.3 mL, 0.5 mL, and 1.0 mL per injection) for 5 consecutive days. This second group of patients was treated for six cycles. All patients received i.t. injection into superficial skin sites or subcutaneous sites except for the following patients: one patient (patient 1007) received injection to a palpable protruding abdominal mass; another patient (patient 1014) received three additional single injections by CT guidance to a single pancreatic metastasis after achieving a complete histological response to a skin site at the midback. Patients receiving multiple injections received these injections in the same lesion. There were no significant differences in the demographics of the two patient groups. A summary of dose, number of injections, and responses are shown in Tables 1 and 2 . Four patients died of complications related to PD during the 16-week study period. Replication-competent retrovirus was negative in sera by PCR in all 17 patients as assessed up to 6 months posttreatment. No significant changes in vital signs or clinical laboratory tests were observed in any patient in relation to the injected vector. Five patients in group II had SD and three patients achieved a PR or CR of the injected lesion in response to the IFN-␥ treatment. However, in group I, only one patient had a response (CR); the rest had progression of disease. Two patients (patients 1009 and 1014) achieved a complete histological response. These responses occurred after weeks 3 and 6, respectively. In patient 1009, the injected lesion regressed and 50% (n ϭ 60 palpable lesions) of the distal lesions also regressed. Distal lesions that regressed had erythema, whereas those that did not had eventually progressed during follow up. Regression of injected and distal lesions occurred within 8 weeks of treatment. A PR at the site of injection was seen in two patients (patients 1012 and 1017). These responses occurred after weeks 6 and 18, respectively. Tumor lesions (injected and distal lesions) were only biopsied from patient 1009. Erythematous lesions assessed by immunohistology had infiltrates of predominantly CD8 ϩ and CD40 ϩ cells. Lesions that had regressed were fibrotic and necrotic with little to moderate infiltrate. Monocytes appeared to be activated and clustered around regions of necrosis and fibrotic tissue. Survival in group I patients was significantly lower compared with survival in group II patients (P ϭ .046) ( Table 2 ). The longest follow-up period was 491 days (group II patient).
Clinical correlations to MAA Ab
Previously, we demonstrated that the sera of normal volunteer donors in general do not have any significant Ab titer to MAA tyrosinase, MAGE-A1, TRP-2, and gp100. 19 -21 Patients with vitiligo or melanoma-associated hypopigmentation (MAH) have been shown to have significant anti-MAA IgG Ab responses. 21 In the analysis of these MAA, anti-IgM Ab was very low or absent. Therefore, in this study, we focused on anti-MAA IgG Ab only. There were no significant differences between groups I and II in baseline Ab levels compared Response of patients to primary lesion and distal lesions in two different treatment groups. Group A patients are patients 1001-1008. Group B patients are 1009 -1017.
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with week 16 Ab levels for all MAA. Similarly, there were no significant changes observed in titer for all anti-MAA Abs between groups I and II. There were also no significant trends for individual anti-MAA Ab responses when the highest titer reached for individual MAA of group I patients was compared with the highest titer reached for group II patients. However, when assessing individual anti-MAA Ab that showed elevation in titers above baseline (day 0) by week 16, the trend showed that group II patients were higher than group I (P ϭ .06) ( Table 3) . When all patients were assessed together, the anti-MAGE-A1 Ab response showed significant (P ϭ .005) Ab titer elevation from baseline (day 0) to week 16. In addition, when all group I and II patients were assessed together, the anti-tyrosinase Ab response showed significant (P ϭ .002) elevation from baseline to week 16 (Table 3) .
Patients were assessed based on optimal clinical response of lesions (PD, CR, PR, and SD) and divided into group A (PD; n ϭ 8) and group B (CR, PR, or SD; n ϭ 9). As expected, group B patients had a significantly (P ϭ .0004) better clinical responses than group A patients ( Table 2) . Changes in individual anti-MAA Ab titers during treatment did not differ significantly between groups A and B, except for changes in the anti-gp100 Ab response (Table 3 ). There was a trend (P ϭ .057) showing elevation of the anti-gp100 Ab response during treatment in group B. If patients were assessed in terms of the number of individual MAA showing an increase in Ab titers from baseline, there was a significant difference (P ϭ .026) between groups A and B. Group B patients had a higher number of anti-MAA responses with increased Ab titers to individual MAA. In comparing the two groups with regard to Ab responses of 0 -1 versus 2-4 MAA, there were significantly (P ϭ .05) more frequent responses to 2-4 MAA observed in group B patients.
Overall, the individual anti-MAA Abs with baseline titers of Յ1:50 were anti-MAGE-A1 Ab (14 of 17 patients) followed by anti-TRP-2 Ab (11 of 17 patients) (Fig 1) . The MAA responses with the highest baseline Ab titers (Ն1:50) were anti-gp100 Ab (14 of 17 patients) followed by anti-tyrosinase Ab (12 of 17 patients) (Fig  1) . This indicated that patients had variable levels of pretreatment anti-MAA Ab responses. Previously, we have shown that melanoma lesions express the MAA tyrosinase, TRP-2, and gp100 proteins with high frequency. 22 MAGE-A1 expression can vary from 30 to 50% depending upon the type of analysis. 19 There are a dozen MAGE-A-related family members, many of which share similar amino acid homology. For example MAGE-A3 and MAGE-A6 share 80% amino acid homology with MAGE-A1. Previously, we have shown that anti-MAGE-A3 Ab will cross-react with MAGE-A1 protein. 10 Therefore, if the melanoma lesion expresses a MAGE-A protein with significant homology to MAGE-A1, it has a significant potential to produce a crossreacting immune response.
All but two patients had an anti-gp100 and antityrosinase Ab response of Ն1:50 after 16 weeks of treatment. Overall during treatment, only one patient (patient 1002) did not produce any significant Ab titer to any of the MAA. This patient had PD and survived only 84 days. A second patient (patient 1003) had a similar response except that the patient developed a slight anti-tyrosinase Ab response at the end of treatment. Of 36 sampling events (serum bleeds) of group A patients during treatment, 13 (36%) showed an elevation over baseline Ab titers. Of 32 sampling events of group B patients during treatment, 22 (69%) showed an elevation over baseline Ab titers. In the two patients (patients 1009 and 1014) that had a CR, significant increases in anti-MAA Ab titers from baseline were noted for anti-MAGE-A1 Ab (Fig 2) . Elevation in anti-MAGE-A1 Ab responses occurred early in the treatment schedule. In patient 1009, elevation in anti-gp100 Ab above baseline also occurred late in treatment, whereas in patient 1014, elevation in anti-tyrosinase Ab above baseline occurred late in treatment. Comparing patients 1012 and 1017 (both had PR), an elevation in anti-MAGE-A1 and anti-gp100 Ab above baseline occurred in patient 1017, whereas in patient 1012, only anti-tyrosinase Ab had a major increase (spike) early in treatment (Fig 2) . However, patient 1012 maintained a continuous high anti-TRP-2 Ab titer before and throughout treatment. The only other patients showing an increase in anti-MAGE-A1 Ab titer above baseline were patients 1004, 1005, and 1011, all of whom showed elevation of Ab titer at the end of treatment. In patient 1004, all other anti-MAA Ab titers decreased below baseline and the patient died early on during treatment. Patient 1011 had The appearance of increased levels of anti-MAA Ab in the sera of patients is concordant with the induction or enhancement of a systemic immune response. The MAA assessed are known to be cytoplasmic MAA. However, whether these MAA are also expressed or cross-reactive with other Ags on the cell surface of melanoma cells is not known. The role of this systemic Ab response in controlling tumor progression is unknown. In this study, only specific anti-MAA Abs were studied, although specific and nonspecific T-cell immunity may also be activated. Assessment of cell-mediated immunity retrospectively is much more difficult logistically on serial bleeds; assays usually require in vitro priming to measure any significant Ag-specific activity, and to date there is no consistency in correlations of Ag-specific T-cell responses to clinical responses. The elicited clinical systemic responses that we observed showed a correlation between positive clinical responses and induction of Ab. This suggests that the systemic immunity that controlled tumor progression may have been induced. Further studies are needed to assess these systemic immune responses induced by primary i.t. treatment and to determine whether they are causative or correlative with clinical responses. The induction and enhancement of immunity by this approach could have implications in controlling distal disease progression. Such findings would have similarities to immunization of patients with cytokine-transfected tumor cells to induce local and systemic immunity. 7, 15 This study demonstrates that modulations of primary lesions can have a significant effect on the immune response of the host to secondary distant lesions.
Overall, most patients produced anti-MAA Ab after treatment in both the single and multiple treatment groups, except patient 1002, who had no significant response. In assessing patients' anti-MAA Ab before treatment, there was no pattern of response observed in either groups I or II with regard to the presence or absence of prior anti-MAA Ab. In the overall assessment of all patients' individual anti-MAA Ab responses, anti-MAGE-A1 Ab and anti-tyrosinase Ab responses showed significant elevation within the 16-week treatment. There are several explanations for these events. The destruction of melanoma cells by IFN-␥ treatment may release MAA in sufficient quantities to induce IgG responses. This is likely due to the type and state of the APCs in the local environment. IFN-␥ can also modulate the Ag processing and presentation capability of APCs. 27, 28 How melanoma cells are killed will play a critical role in Ag release and eventual presentation. Tumor cell death by apoptosis or by a direct lysis mechanism influences how MAA are released.
Recently, molecular mechanisms of action of IFN-␥ on tumor cells have been reported. IFN-␥ has been shown to up-regulate the cyclin-dependent kinase inhibitor p21 (WAF1). 29, 30 The mechanisms of action are suggested to occur through signal transducers and activators of transcription protein-1, which can by activated by IFN-␥. 30 The up-regulation of p21 inhibits entry of cells into the S phase of the cell cycle, thereby causing cell growth arrest. These molecular events are likely to be involved in the responses to i.t. IFN-␥ injections and play a role in the overall control of tumor progression in responding patients. In dividing the patients based on clinical response, group B had significantly better anti-MAA Ab responses. The greater number of different anti-MAA responses correlated with better treatment responses. This suggested that Ab responses to multiple MAA may be used as surrogate response indicators to IFN-␥ retroviral vector treatment. The utility of this anti-MAA Ab response as a surrogate indicator of clinical response needs to be further evaluated in a prospective randomized trial. This study supports previous findings that correlate anti-MAA IgG Ab responses during melanoma cell vaccine treatment in patients as an indicator of a favorable prognosis. 20 It seems likely that the induction of anti-MAA Ab responses is due to tumor cell destruction. We demonstrated previously that AJCC stage III melanoma patients who had been treated with a melanoma cell vaccine had an increase in anti-MAA IgG Ab titers associated with a good prognosis. We have also reported that patients demonstrating hypopigmentation (MAH) have a significant rise in anti-TRP-2 Ab. In a previous study, we observed that vitiligo patients and MAH melanoma patients produce a higher anti-TRP-2 Ab response than melanoma patients. 21 Autoimmunity or melanoma/melanocyte destruction has been associated with specific anti-MAA Ab responses. 21, 31, 32 It is becoming more evident that treatment efficacy correlations are associated with Ab responses to specific MAA. We selected these specific MAA based on previous responses observed in melanoma patients; however, Ab to other types of MAA may also be as informative of response. In summary, the data presented here support the idea that anti-MAA Abs may be appropriate surrogate markers for analyses of immunotherapy of malignant melanoma.
